Squamous Cell Carcinoma of the Oral Cavity Clinical Trial
— NICOOfficial title:
NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
Verified date | July 2020 |
Source | The Clatterbridge Cancer Centre NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is to investigate the use of nivolumab in sequence with standard of care surgery and radiation/chemoradiation in locally advanced oral cavity Squamous cell carcinoma of the oral cavity.
Status | Active, not recruiting |
Enrollment | 21 |
Est. completion date | November 2023 |
Est. primary completion date | May 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | 1. Signed, written informed consent 2. Subjects must be willing and able to comply with scheduled visits and procedures 3. Histologically confirmed squamous cell carcinoma of the oral cavity, (oral tongue (anterior 2/3), gingiva/alveolus, floor of mouth, buccal sulcus, retromolar trigone, and hard palate as defined by ICD-10 codes) 4. Subjects willing to have a fresh biopsy performed, or archival tissue available from diagnostic biopsy meeting requirements set out in laboratory manual. 5. Clinically and/or radiologically staged as T1-4 N1-3 or any T3-4 N0 (unless T4 on the basis of bone invasion only). Staging based upon the AJCC/UICC TNM 8th Edition. 6. Surgery planned as primary treatment modality with patients fit for major resection ± reconstruction surgical procedure. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 8. 18 years or over at time of provision of consent for trial inclusion. 9. Screening laboratory values must meet the following criteria - WBC = 2000/µL - Neutrophils = 1500/uL - Platelets = 100x103/uL - Hemoglobin = 9.0 g/dL - Serum creatinine = 1.5 x ULN or calculated creatinine clearance > 40 mL/min (using the Cockcroft-Gault formula) - AST = 3.0 x ULN - ALT = 3.0 x ULN - Total Bilirubin = 1.5 x ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level of < 3.0x ULN). 10. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug. 11. Women must not be breastfeeding 12. WOCBP must agree to follow instructions for method(s) of contraception for a period of 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo approximately five half-lives. WOCBP randomized/assigned to receive nivolumab should use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo approximately five half-lives) after the last dose of investigational drug. 13. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo approximately five half-lives 14. Males randomized to receive nivolumab who are sexually active with WOCBP must continue contraception for 7 months (90 days plus the time required for nivolumab to undergo approximately five half-lives) after the last dose of investigational drug. Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However they must still undergo pregnancy testing as described in these sections. Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception which have a failure rate of < 1% when used consistently and correctly Exclusion Criteria: 1. Tumours staged as T4 on the basis of bone invasion only and in the absence of nodal metastases. 2. Distant metastases detected, or suspected on imaging 3. Unfit for chemoradiotherapy, due to comorbidity. 4. Previous malignancy requiring treatment within the last 3 years (with the exception of non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, oesophageal endometrial, cervical/dysplasia, melanoma, or breast). Prior head and neck cancer within the last three years is allowed if the tumour was treated with surgery only, and did not require radiotherapy. 5. Prior head and neck radiotherapy 6. On immunosuppressive medication (including steroids at dose equivalent to prednisolone >10mg/day unless used as replacement therapy). 7. Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, lichen planus or other conditions not expected to recur in the absence of an external trigger are permitted to enrol. 8. Known human immunodeficiency virus (HIV) or viral hepatitis infection. 9. Women who are pregnant or breastfeeding 10. Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Clatterbridge Cancer Centre NHS Foundation Trust | Bebington |
Lead Sponsor | Collaborator |
---|---|
The Clatterbridge Cancer Centre NHS Foundation Trust | Bristol-Myers Squibb, University of Liverpool |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease free survival | 1 year disease free survival defined as disease recurrence or death at 12 months from surgery | Patients will be followed up for 12 months following surgery | |
Primary | Recruitment Rate | Measured as the number of patients/site/month | Period of recruitment | |
Secondary | Overall survival | Overall survival measured as the time from surgery to death by any cause | Patients will be followed up for 12 months following surgery | |
Secondary | Surgical complications - Infection rate | Measured as incidence of post surgical infection | up to 8 weeks post date of surgery | |
Secondary | Surgical complications - length of hospital admission | Measured as length of time between admission for surgery and discharge | up to 8 weeks post date of surgery | |
Secondary | Surgical complications - free flap failure | Measured as incidence of failure of free flap reconstruction | up to 8 weeks post date of surgery | |
Secondary | Surgical complications - perioperative (30-day mortality) | Measured as Incidence of death post surgery by any cause | up to 30 days post date of surgery | |
Secondary | Assessment of adverse events | Assessment of adverse events, adverse events recorded will be classified using CTCAE v4 | Following participants informed consent up to 100 days following last dose of trial treatment. | |
Secondary | The change of Quality of Life: EORTC QLQ-C30 v3 | The change of quality of life is measured using the EORTC QLQ-C30 v3 quality of life questionnaire. The quality of life scale is transformed into a score of 0 to 100, derived by a 4-point Likert scale. A higher score represents a higher level of quality of life. | Patients will be followed up for 12 months following surgery | |
Secondary | The change of symptom | The change of symptoms is measured using the EORTC quality of life questionnaire (EORTC QLQ) Head and Neck cancer module (QLQ-H&N35). The symptom scale is transformed into a score of 0 to 100, derived by a 4-point Likert scale. A higher score represents a higher level of symptom. | Patients will be followed up for 12 months following surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540899 -
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT01108042 -
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06380686 -
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
|
||
Completed |
NCT02873819 -
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
|
Phase 2 | |
Active, not recruiting |
NCT04387682 -
Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients
|
N/A | |
Completed |
NCT01321892 -
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium
|
N/A | |
Completed |
NCT01636544 -
Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity
|
N/A | |
Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
Withdrawn |
NCT04831450 -
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 | |
Recruiting |
NCT04191460 -
Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
|
Phase 2 | |
Recruiting |
NCT06030440 -
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 | |
Terminated |
NCT01077869 -
A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis
|
Phase 1 | |
Completed |
NCT02609386 -
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
|
Phase 2 | |
Not yet recruiting |
NCT05452408 -
Antitumor-B KAC PK Study
|
Phase 1 | |
Not yet recruiting |
NCT03364166 -
Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma
|
N/A | |
Terminated |
NCT02331875 -
Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
|
Phase 1/Phase 2 | |
Completed |
NCT01265849 -
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
|
Phase 3 | |
Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT03575598 -
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
|
Early Phase 1 | |
Active, not recruiting |
NCT03459729 -
Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
|
Early Phase 1 |